Guanidinoacetate methyltransferase deficiency: differences of creatine uptake in human brain and muscle
Introduction
Guanidinoacetate methyltransferase (GAMT, EC 2.1.1.2) catalyzes the formation of creatine by methylation of its precursor guanidinoacetate (GAA) (Fig. 1). After transport from the liver, pancreas, and kidney into nerve and muscle tissue, creatine is converted into phosphocreatine by the creatine kinase reaction. Phosphocreatine is re-utilized to generate ATP whenever needed. Following the first characterization of a GAMT-deficient patient in 1994, [1] seven patients have been reported so far [2], [3], [4], [5], [6], [7]. Whereas affected patients present with mental retardation and epilepsy, a few patients also exhibited signs of an extrapyramidal movement disorder [1], [2], [5], [7]. In vivo proton magnetic resonance spectroscopy (1H-MRS) revealed an almost complete depletion of brain creatine/phosphocreatine and an accumulation of GAA in all patients. Treatment with creatine monohydrate has been shown to increase brain creatine concentration leading to partial clinical improvement. Dietary arginine restriction in combination with ornithine supplementation has been proposed to lower the concentration of potentially neurotoxic GAA [8].
In contrast to the severe brain involvement, affected patients show no or only mild muscular symptoms [5], [7]. This remains poorly understood, considering that skeletal muscle is another tissue with significant energy demands. Skeletal muscle has not been investigated in newly diagnosed GAMT-deficient patients prior to therapy except for one adult [7]. To study muscle creatine uptake, we performed 1H-MRS and phosphorus magnetic resonance spectroscopy (31P-MRS) of both brain and skeletal muscle before and on treatment of a 7-year-old child diagnosed with GAMT deficiency.
Section snippets
Case report
The 7-year-old male, the product of an uncomplicated 38-week gestation, is the first child of consanguineous healthy Turkish parents. Neonatal hypothermia and feeding difficulties were observed. He sat at 10 months, crawled at 12 months, and walked without support at 18 months. During the following years, severe mental retardation with speech impairment became evident. He developed autistic features with increasing aggressiveness towards individuals and objects. Moderate generalized hypotonia
Metabolite, enzymatic, and molecular genetic analyses
GAA concentrations in plasma, urine, and CSF were markedly elevated (Table 1). Creatinine in serum was in the low normal range, and creatinine excretion during 24 h was decreased (Table 1). When calculated in relation to the initial urinary creatinine excretion, the elevation of the urine GAA concentration before treatment was more drastic (1007 mmol/mol creatinine; controls 10–308). The diagnosis of GAMT deficiency was confirmed by enzyme analysis in cultured fibroblasts (<0.1 nmol/h/mg protein;
Discussion
In a 7-year-old boy with marked developmental delay and epilepsy, GAMT deficiency was suspected by a positive Sakaguchi reaction and subsequent quantitative measurements of GAA. The diagnosis was confirmed by 1H-and 31P-MRS in brain showing an almost complete absence of total creatine and a marked accumulation of GAA, absent GAMT activity in fibroblasts and detection of homozygosity for a new frameshift mutation.
In this patient, MRS of skeletal muscle was performed prior to treatment to
Acknowledgements
We are grateful to Dr. H. Korall, Klinik für Kinder-und Jugendmedizin Reutlingen, School of Medicine, University of Tübingen, Reutlingen, Germany, for analysis of creatine in CSF.
References (28)
- et al.
Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: diagnostic tools for a new inborn error of metabolism
J. Pediatr.
(1997) - et al.
Guanidinoacetate methyltransferase deficiency: new clinical features
Pediatr. Neurol.
(1997) - et al.
Improving treatment of guanidinoacetate methyltransferase deficiency: reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation
Mol. Genet. Metab.
(2001) - et al.
Analysis of guanidinoacetate and creatine by isotope dilution electrospray tandem mass spectrometry
Clin. Chim. Acta
(2001) - et al.
Guanidinoacetate methyltransferase (GAMT) deficiency: non-invasive enzymatic diagnosis of a newly recognized inborn error of metabolism
Clin. Chim. Acta
(2000) - et al.
Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy
J. Magn. Reson
(1986) - et al.
Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism
Lancet
(1996) - et al.
Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study
Brain Res. Mol. Brain Res.
(2001) - et al.
Guanidino compounds in guanidinoacetate methyltransferase deficiency, a new inborn error of creatine synthesis
Metabolism
(1997) - et al.
Creatine deficiency in the brain: a new, treatable inborn error of metabolism
Pediatr. Res.
(1994)
Mental retardation and behavior problems as presenting signs of a creatine synthesis defect
Ann. Neurol.
Brain creatine depletion: guanidinoacetate methyltransferase deficiency (improving with creatine supplementation)
Neurology
Presence of muscle creatine in a patient with guanidinoacetate methyltransferase (GAMT) deficiency
J. Inherit. Metab. Dis.
Lack of creatine in muscle and brain in an adult with GAMT deficiency
Ann. Neurol.
Cited by (55)
Magnetic Resonance Spectroscopy and its Clinical Applications: A Review
2017, Journal of Medical Imaging and Radiation SciencesCitation Excerpt :In contrast, some situations such as gliosis in white matter may increase its concentration slightly. The complete lack of Cr signal implies a deficiency in Cr production, as in guanidinoacetate methyltransferase imperfection [59–62] or in L-arginine glycine amidinotransferase shortcoming [63], or to a Cr transporter failure [64]. With short TE, some other signals can be observed.
Guanidinoacetate methyltransferase (GAMT) deficiency: Outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring
2014, Molecular Genetics and MetabolismCitation Excerpt :Strategies to reduce GAA levels include substrate deprivation via an arginine-restricted diet as well as competitive inhibition of AGAT activity via high-dose l-ornithine supplementation [4–8]. Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys [9–11]. Since GAMTdeficiency was first described in 1994 [12], more than 50 patients have been reported in the literature [13], but no guidelines have been established regarding the use of the various treatment strategies.
Use of MRS in Inborn Errors of Metabolism. Canavan's Disease and MRS in Differential Diagnosis.
2013, Magnetic Resonance Spectroscopy: Tools for Neuroscience Research and Emerging Clinical ApplicationsEvidence-based treatment of guanidinoacetate methyltransferase (GAMT) deficiency
2013, Molecular Genetics and MetabolismCitation Excerpt :Fig. 1 shows the results of MR spectroscopy with short time to echo (TE) (35 ms) and long TE (288 ms) echo time in patient 4 at time of diagnosis and after 1 year of therapy. A prominent peak corresponding to guanidinoacetate (GAA) at 3.8 ppm was present at time of diagnosis (Fig. 1A), as seen in other patients with GAMT deficiency [10,14]. There are many different chemicals with a chemical shift similar to guanidino compounds with the short TE (35 ms), rendering peak identification difficult (Figs. 1A, C).
Biochemical, molecular, and clinical diagnoses of patients with cerebral creatine deficiency syndromes
2013, Molecular Genetics and MetabolismCitation Excerpt :Dietary restriction of arginine using protein restriction and supplementation with ornithine to reduce the available substrate for AGAT and provide product feedback inhibition has been reported for several GAMT patients. However, while GAA levels decreased, the long term benefits remain to be established [24,41,43]. Effective treatment for CT1 deficiency remains elusive.